Holen Sie sich die Stockscreener-App
0.776
8.71%
-0.074
Vorhandelsmarkt:
.80
0.024
+3.09%
Schlusskurs vom Vortag:
$0.85
Offen:
$0.8696
24-Stunden-Volumen:
6.89M
Relative Volume:
3.53
Marktkapitalisierung:
$123.11M
Einnahmen:
$3,000
Nettoeinkommen (Verlust:
$-108.00M
KGV:
-0.517
EPS:
-1.501
Netto-Cashflow:
$-87.84M
1W Leistung:
+16.85%
1M Leistung:
-9.83%
6M Leistung:
-64.07%
1J Leistung:
-62.87%
1-Tages-Spanne:
$0.776
$0.8696
1-Wochen-Bereich:
$0.6777
$0.872
52-Wochen-Spanne:
$0.3772
$2.445
Fractyl Health Inc Stock (GUTS) Company Profile
Firmenname
Fractyl Health Inc
Sektor
Branche
Telefon
781-902-8800
Adresse
3 VAN DE GRAAFF DRIVE, BURLINGTON
Compare GUTS vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
GUTS
Fractyl Health Inc
|
0.776 | 134.85M | 3,000 | -108.00M | -87.84M | -1.501 |
VRTX
Vertex Pharmaceuticals Inc
|
453.17 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
614.73 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
878.49 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
281.90 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
156.58 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Fractyl Health Inc Stock (GUTS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-30 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2025-09-15 | Eingeleitet | H.C. Wainwright | Buy |
| 2025-08-28 | Eingeleitet | Ladenburg Thalmann | Buy |
| 2024-02-28 | Eingeleitet | Evercore ISI | Outperform |
| 2024-02-27 | Eingeleitet | BofA Securities | Buy |
| 2024-02-27 | Eingeleitet | Morgan Stanley | Overweight |
Alle ansehen
Fractyl Health Inc Aktie (GUTS) Neueste Nachrichten
GUTS SEC FilingsFractyl Health 10-K, 10-Q, 8-K Forms - Stock Titan
Fractyl Health director Ajay Royan buys $19,596 in company stock - Investing.com UK
Fractyl Health (NASDAQ: GUTS) director adds 23,000 shares in open-market buy - Stock Titan
Fractyl Health, Inc. 8-K Filing June 2026: Company Information, Nasdaq Listing, and Executive Details - Minichart
Fractyl Health Inc (GUTS) Cleared for RJVA-001 Trial. Let’s Look At Funding - Insider Monkey
Fractyl Health director William Bradley buys $50,328 in stock - Investing.com
Fractyl Health (NASDAQ: GUTS) 2026 meeting backs board and auditor - Stock Titan
Fractyl Health (GUTS) director buys stock and receives 22,500 options - Stock Titan
Fractyl Health (GUTS) awards 22,500 stock options to board director - Stock Titan
Fractyl Health (GUTS) awards director 22,500 options at $0.7318 - Stock Titan
Fractyl Health (GUTS) director Marc Elia receives 22,500-share stock option grant - Stock Titan
Fractyl Health (GUTS) director receives 22,500-stock-option board compensation grant - Stock Titan
Director Clive Meanwell gets 22,500 options at Fractyl Health (GUTS) - Stock Titan
Fractyl Health (NASDAQ: GUTS) director buys shares and receives options - Stock Titan
Fractyl Health (GUTS) CEO buys 25,000 open-market shares - Stock Titan
Fractyl Health CFO Smith Weber Lara purchases $13,708 in stock By Investing.com - Investing.com South Africa
Fractyl Health CFO Smith Weber Lara purchases $13,708 in stock - Investing.com
[Form 4] FRACTYL HEALTH, INC. Insider Trading Activity - Stock Titan
Fractyl Health reports one-year data on weight maintenance therapy - Investing.com UK
GUTS Reiterates by HC Wainwright & Co. -- Price Target Maintained at $8.00 - GuruFocus
Fractyl Health Reports Positive One-Year Results from REVEAL-1 Open-Label Study of Revita Procedure for Post-GLP-1 Weight Maintenance - marketscreener.com
Fractyl Health Reports Positive One-Year REVEAL-1 Open-Label Results Showing Sustained Post-GLP-1 Weight Maintenance After a Single Revita® Procedure - markets.businessinsider.com
Fractyl Health Highlights One-Year Revita Obesity Results - TipRanks
Fractyl Health reports one-year data on weight maintenance therapy By Investing.com - Investing.com South Africa
Fractyl Health Reports Positive One-Year Results from REVEAL-1 Cohort, Highlighting Revita's Efficacy in Sustaining Weight Loss Post-GLP-1 Therapy - Quiver Quantitative
Revita study shows durable post-GLP-1 weight loss at Fractyl Health (GUTS) - Stock Titan
Fractyl Health Reports Positive One-Year REVEAL-1 - GlobeNewswire
Fractyl Health names Mike Zumdahl as market access head By Investing.com - Investing.com South Africa
Fractyl Health Appoints Mike Zumdahl as Senior Vice President, Market Access and Commercial Strategy - The Manila Times
Fractyl Health names Mike Zumdahl as market access head - Investing.com
Nearly 1M leave GLP-1 therapy monthly; Fractyl hires market-access lead - Stock Titan
Fractyl Health, Inc. Announces Appointment of Mike Zumdahl to Senior Vice President, Market Access and Commercial Strategy - marketscreener.com
Fractyl Health Inc. (GUTS) Declines 2.7% as Stock Tests Critical Support Near $0.78Put Call Ratio - newsline.com
Fractyl Health (GUTS) Dips 3% as Stock Hovers Near Critical Support at $0.85Algorithmic Stock Picks - The Legal Advocate
GUTS Stock Chart | FRACTYL HEALTH INC (NASDAQ:GUTS) - ChartMill
Fractyl Health Q1 earnings call highlights - MSN
Fractyl Health Inc. (GUTS) Q1 2026 Earnings: Narrower Loss Surprises, Stock SlidesEarnings Cycle Report - thelegaladvocate.com
GUTS - Intellectia AI
Fractyl Health’s Pivotal Year: Inside the Earnings Call - TipRanks
Earnings call transcript: Fractyl Health Q1 2026 reports EPS beat, shares surge - Investing.com
Fractyl targets early Q4 2026 REMAIN-1 pivotal readout amid plans for late Q4 2026 de novo submission - MSN
Fractyl Health (GUTS) Is Up 14.0% After First GLP-1 Gene Therapy Trial Win And Profit Turnaround - Yahoo Finance
First human GLP-1 gene therapy trial gets green light - NewsNation
Nantahala’s 16.1M-share stake disclosed in Fractyl Health (NASDAQ: GUTS) - Stock Titan
[SCHEDULE 13G/A] FRACTYL HEALTH, INC. Amended Passive Investment Disclosure - Stock Titan
BofA Securities Maintains Fractyl Health(GUTS.US) With Buy Rating, Announces Target Price $2 - Moomoo
Fractyl Health (GUTS) stock jumps 21% after hours: Here's what you should know - MSN
TradingKey - TradingKey
A Look At Fractyl Health (GUTS) Valuation After New Gene Therapy Trial Approval And First Quarter Net Income - Yahoo Finance
Analysts Offer Insights on Healthcare Companies: Fractyl Health, Inc. (GUTS), UnitedHealth (UNH) and TELA Bio (TELA) - The Globe and Mail
SilverArc and Devesh Gandhi report 3.6M shares in Fractyl Health (GUTS) - Stock Titan
Finanzdaten der Fractyl Health Inc-Aktie (GUTS)
Umsatz
Nettogewinn
Free Cashflow
ENV
Fractyl Health Inc-Aktie (GUTS) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| BRADLEY WILLIAM | Director |
Jun 10 '26 |
Buy |
0.73 |
68,493 |
50,329 |
84,622 |
| Sheffield Ian | Director |
Jun 10 '26 |
Buy |
0.73 |
35,000 |
25,529 |
35,000 |
| Rajagopalan Harith | Chief Executive Officer |
Jun 10 '26 |
Buy |
0.73 |
25,000 |
18,252 |
540,557 |
| Smith Weber Lara | Chief Financial Officer |
Jun 08 '26 |
Buy |
0.69 |
20,000 |
13,708 |
20,000 |
| Rajagopalan Harith | Chief Executive Officer |
Dec 04 '25 |
Buy |
1.92 |
10,416 |
19,999 |
501,745 |
1.27%
1.43%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):